Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Corporate Overview
Management Team
Board of Directors
Social Responsibility
NPC Blog
Code of Ethics
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Corp. (OTCBB: NPHC) is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.

Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Mission Statement

Nutra Pharma is dedicated to the success of its patients, customers, investors and business partners through its development and acquisition of innovative pharmaceutical and life science solutions that will improve the lives of people throughout the world.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
September 09, 2015
Nutra Pharma To Present at Upcoming Investment Conference

September 08, 2015
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration for the Treatment of Juvenile Multiple Sclerosis

July 15, 2015
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics